Hostname: page-component-7dd5485656-s6l46 Total loading time: 0 Render date: 2025-10-29T10:49:13.395Z Has data issue: false hasContentIssue false
  • English
  • Français

Tardive Dyskinesia: Its Relation to Neuroleptic and Antiparkinson Drugs

Published online by Cambridge University Press:  29 January 2018

Ibrahim Turek ,
Albert A. Kurland ,
Thomas E. Hanlon  and
Mark Bohm
Ibrahim Turek
Affiliation:
Maryland State Psychiatric Research Center, Baltimore, Maryland 21228
Albert A. Kurland
Affiliation:
Maryland State Psychiatric Research Center, Baltimore, Maryland 21228
Thomas E. Hanlon
Affiliation:
Maryland State Psychiatric Research Center, Baltimore, Maryland 21228
Mark Bohm
Affiliation:
Formerly with the Maryland State Psychiatric Research Center, Baltimore, Maryland 21228
Get access Rights & Permissions [Opens in a new window]

Extract

Although accounts of neurological complications resulting from the use of neuroleptic drugs have consistently appeared in the psychiatric literature since the introduction of reserpine in the 1930's, serious concern about the permanence of these effects has been a rather recent development. As early as 1956, reports by Ey, Faure, and Rappard (10) and by Hall, Jackson, and Swain (13) called attention to the persistence of extrapyramidal symptoms several months after the cessation of extended chlorpromazine treatment. Emphasis on the persistence of dyskinetic symptoms after extended treatment subsequently appeared in reports by Broussolle and Rosier (2), Sigwald, Bouttier, and Courvoisier (20), and Ayd (1). In a survey of reversible and irreversible dyskinesia after treatment with reserpine, chlorpromazine, perphenazine and electroconvulsive therapy, Uhrbrand and Faurbye (22) noted the late appearance of the complication and termed it ‘tardive dyskinesia’.

Information

Type
Research Article
Information
The British Journal of Psychiatry , Volume 121 , Issue 565 , December 1972 , pp. 605 - 612
Copyright
Copyright © Royal College of Psychiatrists, 1972 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1 Ayd, F. J. (1966). ‘Persistent dyskinesia: a neurologic complication of major tranquilizers.’ International Drug Therapy Newsletter, 1, No. 6.Google Scholar
2 Broussolle, P., and Rosier, Y. (1959). ‘Evolution des symptomes neurologiques dus aux neuroleptiques.’ Annales Médico-Psychologiques, 117, 140–51.Google Scholar
3 Crane, G. E. (1968). ‘Dyskinesia and neuroleptics.’ Archives of General Psychiatry, 19, 700–3.Google Scholar
4 Crane, G. E. (1968 Supp.). ‘Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature.’ American Journal of Psychiatry, 124, 40–8.CrossRefGoogle ScholarPubMed
5 Crane, G. E. Ruiz, P., Kernohan, W. J., Wilson, W., and Royalty, N. (1969). ‘Effects of drug withdrawal in tardive dyskinesia.’ Activitas Nervosa Superior, 11, 30–5.Google Scholar
6 Crane, G. E. (1970). ‘High doses of trifluoperazine and tardive dyskinesia.’ Archives of Neurology, 22, 176–80.CrossRefGoogle ScholarPubMed
7 Degkwitz, R., Wenzel, W., Biusack, K. F., Herbert, H., and Luxenburoer, O. (1966). ‘Zum Problem der terminalen extrapyramidalen Hyperkinesen, an Hand von 1600 langfristig mit Neuroleptica Behandelten.’ Arzneimittelforschung, 16, 276–8.Google Scholar
8 Druchman, R., Seelinger, D., and Thulin, B. (1962). ‘Chronic involuntary movements induced by phenothiazines.’ Journal of Nervous and Mental Diseases, 135, 69–76.Google Scholar
9 Evans, J. H. (1965). ‘Persistent oral dyskinesia in treatments with phenothiazine derivatives.’ Lancet, i, 458–60.Google Scholar
10 Ey, H., Faure, H., and Rappard, P. (1956). ‘Les réactions d'intolerance vis-a-vis de la chlor-promazine.’ Encéphale, 45, 790–6.Google Scholar
11 Faurbye, A., Rasch, P. J., Petersen, P. B., Brandborg, G., and Pakkenberg, H. (1964). ‘Neurological symptoms in pharmacotherapy of psychosis.’ Acta Psychiatrica Scandinavica, 40, 10–27.CrossRefGoogle Scholar
12 Haddenbrock, S. (1964). ‘Prolonged hyperkinetic syndromes following long term treatment with high doses of neuroleptic agents,’ in Begleitwïrkungen and Nusserfolge der psychiatrischen Pharmakotherapic (ed. H. Kranz and K. Heinrick). Stuttgart.Google Scholar
13 Hall, R. A., Jackson, R. B., and Swain, J. M. (1956). ‘Neurotoxic reactions resulting from chlorpro-mazine administration.’ Journal of the American Medical Association, 141, 214–18.Google Scholar
14 Hunter, R., Earl, C. J., and Janz, D. (1964). ‘A syndrome of abnormal movements and dementia in leucotomized patients treated with pheno-thiazines.’ Journal of Neurology, Neurosurgery and Psychiatry, 27, 219–23.CrossRefGoogle Scholar
15 Kline, N. S. (1968 Supp.). ‘On the rarity of irreversible oral dyskinesia following phenothiazines.’ American Journal of Psychiatry, 124, 48–54.Google Scholar
16 Paulson, G. E. (1968). ‘Prominent or complex dyskinesias in the aged.’ Geriatrics, 23, 105–10.Google ScholarPubMed
17 Rodova, A., and Nahunek, K. (1964). ‘Persistent dyskinesia after phenothiazines.’ Československá Psychiatrie, 60, 250–4.Google Scholar
18 Schmidt, W., and Jarcho, L. W. (1966). ‘Persistent dyskinesias following phenothiazine therapy.’ Archives of Neurology, 14, 369–77.Google Scholar
19 Shaffer, J. W., Forbes, J. A., and DeFelice, E. A. (1967). ‘Some suggested approaches to the analysis of chronic toxicity drug administration data.’ Toxicology and Applied Pharmacology, 10, 514–22.Google Scholar
20 Sigwald, J., Boutter, D., and Courvoisier, S. (1959). ‘Les accidents neurologiques des medications neuroleptiques.’ Review of Neurology, 100, 553–95.Google Scholar
21 Turunen, S., and Achte, K. A. (1967). ‘The buccolinguo-masticatory syndrome as a side effect of neuroleptics therapy.’ Psychiatric Quarterly, 41, 268–75.Google Scholar
22 Uhrbrand, L., and Faurbye, A. (1960). ‘Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy.’ Psychopharmacologica, 1, 408–18.Google Scholar
23 Wertheimer, J. (1965). ‘Syndromes extra-pyramidaux permanents consécutifs a l'administration prolongée de neuroleptiques.’ Schweizersche Archiv für Neurologie, Neurochiurigie und Psychiatrie, 95, 120–73.Google Scholar
24 Brandon, S., McClelland, H. A., and Protheroe, C. (1971). ‘A study of facial dyskinesia in a mental hospital population.’ British Journal of Psychiatry, 118, 171–84.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.